lngfrmlogo

antibody drug conjugates

OBI Pharma Receives FDA Approval for Phase I/II Trial of Innovative Cancer Treatment OBI-902

OBI Pharma gains FDA approval for a Phase I/II trial of OBI-902, a novel cancer treatment. This innovative antibody-drug conjugate aims to improve outcomes for patients with advanced solid tumors.

By
LNGFRM Team
  • 05/02/2025
  • - BiotechnologyPharmaceuticals
"Abstract illustration featuring two scientists in white lab coats working at desks, set against a vibrant yellow background. A large DNA double helix and stylized molecular structures are portrayed in the scene."
  • Biotechnology
OBI Pharma Receives FDA Approval for Phase I/II Trial of Innovative Cancer Treatment OBI-902
LNGFRM Team
© 2026 LNGFRM. All rights reserved.